港股異動 | 香港醫思醫療(2138.HK)再創新高 預期中國內地診所及服務中心年度銷售額同比增加不少於60%
格隆匯4月20日丨香港醫思醫療集團(2138.HK)高開高走,現漲幅擴大至逾5%,報8.92港元,高見8.98港元再創歷史新高,總市值96億港元。

香港醫思醫療集團昨日盤後公吿,集團預期其位於中國內地的診所及服務中心截至2021年3月31日止年度初步未經審核銷售額錄得較去年同期不少於60%升幅。
集團於期內下半年在深圳新設了3間新的診所和服務中心。截至2021年3月31日,集團在中國大陸僱用13名全職專屬註冊醫生,並運營15間診所和服務中心。集團預計於2021年12月底前於深圳及廣州開設另外6間新的診所和服務中心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.